29547
Regulating Together: Emotion Regulation Treatment for Children and Teens with ASD in an Intensive, Group, Parent-Assisted Program Pilot Trial
Objectives: Our group developed Regulating Together (RT), a unique comprehensive program including both caregivers and children in a group format that uses elements of CBT, ABA, and Mindfulness approaches. Here, we aim to determine the feasibility and efficacy from a pilot study containing child (8-12 years) and adolescent (13-18 years) groups that met twice weekly for 5 weeks.
Methods: We examined a multi-diagnostic clinical RT group via a chart review of 59 participants (40 8-12, 19 13-18), 31 with ASD (20 8-12, 11 13-18), comparing pre- and post-treatment scores on the Aberrant Behavior Checklist, Pediatric Quality of Life Family Impact Module (PedsQL), and clinician rated CGI-I7. Each age group was analyzed separately.
Results: The ASD child group had statistically significant changes on all subscales of the Aberrant Behavior Checklist and the ASD teen group had significant changes on the Irritability, Lethargy, and Stereotypy subscales. Regarding CGI-I, 53% of the children were rated as Much Improved, 24% minimally improved, 21% no change, and one participant minimally worse post-treatment and 28.6% of adolescents were rated as Much Improved and 71.4% minimally improved. Parents provided overwhelmingly positive feedback in regard to learning, enjoying the program, and increased confidence in behavior management. There was a 15% attrition and a 13% absence rate suggesting overall feasibility. No significant changes were found on the PedsQL for either group.
Conclusions: ER is a critically under-studied and under-treated issue in ASD and other developmental disorders leading to high rates of hospitalizations and social and academic difficulties. Thus, we developed a short-term parent-assisted group intervention approach aimed at increasing ER. Our novel Regulating Together treatment program shows promising short-term preliminary findings, and thus indicate further evaluation of efficacy, identification of treatment responder characteristics and active components, and long-term benefits is warranted.